Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
157 hedge funds and large institutions have $2.63B invested in Akero Therapeutics in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 71 increasing their positions, 39 reducing their positions, and 25 closing their positions.
82% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 39
43% more capital invested
Capital invested by funds: $1.84B → $2.63B (+$793M)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
4% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 25
1% more funds holding
Funds holding: 156 → 157 (+1)
0.46% less ownership
Funds ownership: 102.34% → 101.88% (-0.46%)
32% less call options, than puts
Call options by funds: $40.8M | Put options by funds: $60.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GA
General Atlantic
New York
|
+$81.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$66.3M |
| 3 |
PA
Perceptive Advisors
New York
|
+$64.9M |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$52.4M |
| 5 |
CC
Commodore Capital
New York
|
+$40.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ST
Skorpios Trust
Limassol,
Cyprus
|
-$75.6M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$65.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$24.3M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$15.8M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.9M |
AKRO Hedge Fund Activity: Q2 2023 in Review
157 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q2 2023, worth a combined $2.63B — up 43% from $1.84B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new AKRO positions and 25 closed out — a net gain of 1 holder — while 71 added to existing stakes and 39 trimmed.
The largest buyer was General Atlantic, opening a new position worth an estimated $81.8M. The largest seller was Skorpios Trust, cutting an estimated $75.6M.
- 157 institutional investors held Akero Therapeutics (AKRO) as of Q2 2023, up from 156 in Q1 2023.
- Funds reported $2.63B of Akero Therapeutics stock for Q2 2023, up 43% quarter-over-quarter.
- 26 funds opened new Akero Therapeutics positions in Q2 2023 and 25 closed out, a net change of +1 holder.
- The largest Akero Therapeutics buyer in Q2 2023 was General Atlantic, an estimated $81.8M added.
- The largest Akero Therapeutics seller in Q2 2023 was Skorpios Trust, an estimated $75.6M sold.
Based on aggregated 13F filings for Q2 2023.